MyoKardia is dedicated to revolutionizing the treatment of genetic heart diseases. The company's initial focus includes hypertrophic and dilated cardiomyopathy (HCM and DCM), diseases for which there have been no treatment advances in more than 50 years.
By combining leading-edge cardiovascular genetics with recent advances in heart muscle biochemistry, MyoKardia seeks to usher in an era of precision medicine that will dramatically improve the treatment of cardiomyopathies and make a meaningful difference in the lives of millions of people suffering from cardiovascular diseases. Available treatments for patients suffering from these forms of heart disease have been approved for other illnesses and only treat the symptoms of their disease. MyoKardia’s approach targets the genetic mutations that are the underlying causes of cardiomyopathy, addressing the fundamental mechanisms of the disease. This genetically targeted approach has the potential to revolutionize the treatment of cardiomyopathies, and ultimately a broader spectrum of cardiovascular disease, including heart failure.
Launched in 2012 by Third Rock Ventures, MyoKardia was founded by world-class experts in cardiovascular disease, cardiac muscle biology and genetics.
In 2014, MyoKardia forged a strategic worldwide collaboration with Sanofi to discover, develop and advance first-of-its-kind targeted therapeutics for HCM and DCM.